{
    "hands_on_practices": [
        {
            "introduction": "The clinical management of hepatocellular carcinoma often begins with screening high-risk populations, such as patients with cirrhosis. However, the raw sensitivity and specificity of a test like alpha-fetoprotein ($AFP$) don't tell the whole story of its diagnostic power. This exercise provides hands-on practice applying probability principles to calculate a test's positive and negative predictive values, which are essential for understanding a biomarker's real-world performance and clinical utility .",
            "id": "4380795",
            "problem": "A hospital implements a surveillance program for hepatocellular carcinoma (HCC) in a cohort of patients with cirrhosis. Alpha-fetoprotein (AFP) is used as a binary screening test with a fixed threshold. In this cohort, the following performance characteristics and disease frequency are well established from prior validation work: sensitivity $0.60$, specificity $0.90$, and disease prevalence $0.20$. Using only the core probabilistic definitions from diagnostic test evaluation and Bayesâ€™ theorem, derive expressions for the positive predictive value (PPV), defined as $P(\\text{Disease} \\mid \\text{Test positive})$, and the negative predictive value (NPV), defined as $P(\\text{No disease} \\mid \\text{Test negative})$, in terms of sensitivity, specificity, and prevalence. Then compute the numerical values for PPV and NPV for this cohort.\n\nReport your final answer as a row vector $[PPV \\; NPV]$ rounded to three significant figures and expressed as decimals (do not use a percent sign).",
            "solution": "The problem statement is evaluated as valid, as it is scientifically grounded in probability theory, well-posed with sufficient information, and objective in its language. We may therefore proceed with a formal solution.\n\nLet us define the events and probabilities based on the provided information.\nLet $D$ be the event that a patient has hepatocellular carcinoma (disease).\nLet $D^c$ be the event that a patient does not have the disease.\nLet $T^+$ be the event that the alpha-fetoprotein (AFP) test result is positive.\nLet $T^-$ be the event that the test result is negative.\n\nThe problem provides the following probabilities:\nThe sensitivity of the test, $\\text{Se}$, is the probability of a positive test given the patient has the disease:\n$$P(T^+ \\mid D) = \\text{Se} = 0.60$$\nThe specificity of the test, $\\text{Sp}$, is the probability of a negative test given the patient does not have the disease:\n$$P(T^- \\mid D^c) = \\text{Sp} = 0.90$$\nThe prevalence of the disease, $P_{\\text{prev}}$, is the prior probability of a patient having the disease in the cohort:\n$$P(D) = P_{\\text{prev}} = 0.20$$\n\nFrom these, we can derive complementary probabilities:\nThe probability of a patient not having the disease is:\n$$P(D^c) = 1 - P(D) = 1 - P_{\\text{prev}} = 1 - 0.20 = 0.80$$\nThe false positive rate is the probability of a positive test given the patient does not have the disease:\n$$P(T^+ \\mid D^c) = 1 - P(T^- \\mid D^c) = 1 - \\text{Sp} = 1 - 0.90 = 0.10$$\nThe false negative rate is the probability of a negative test given the patient has the disease:\n$$P(T^- \\mid D) = 1 - P(T^+ \\mid D) = 1 - \\text{Se} = 1 - 0.60 = 0.40$$\n\nThe first part of the task is to derive an expression for the positive predictive value ($\\text{PPV}$), defined as $P(D \\mid T^+)$, in terms of sensitivity, specificity, and prevalence. We apply Bayes' theorem:\n$$\\text{PPV} = P(D \\mid T^+) = \\frac{P(T^+ \\mid D) P(D)}{P(T^+)}$$\nThe denominator, $P(T^+)$, is the total probability of a positive test result. We can expand it using the law of total probability:\n$$P(T^+) = P(T^+ \\mid D) P(D) + P(T^+ \\mid D^c) P(D^c)$$\nSubstituting the definitions of sensitivity, specificity, and prevalence:\n$$P(T^+) = (\\text{Se} \\times P_{\\text{prev}}) + ((1 - \\text{Sp}) \\times (1 - P_{\\text{prev}}))$$\nSubstituting this expression back into the formula for $\\text{PPV}$, we obtain the general expression:\n$$\\text{PPV} = \\frac{\\text{Se} \\times P_{\\text{prev}}}{(\\text{Se} \\times P_{\\text{prev}}) + (1 - \\text{Sp})(1 - P_{\\text{prev}})}$$\n\nThe second part of the task is to derive an expression for the negative predictive value ($\\text{NPV}$), defined as $P(D^c \\mid T^-)$, in terms of the same parameters. We again apply Bayes' theorem:\n$$\\text{NPV} = P(D^c \\mid T^-) = \\frac{P(T^- \\mid D^c) P(D^c)}{P(T^-)}$$\nThe denominator, $P(T^-)$, is the total probability of a negative test result, which can be expanded using the law of total probability:\n$$P(T^-) = P(T^- \\mid D) P(D) + P(T^- \\mid D^c) P(D^c)$$\nSubstituting the definitions of sensitivity, specificity, and prevalence:\n$$P(T^-) = ((1 - \\text{Se}) \\times P_{\\text{prev}}) + (\\text{Sp} \\times (1 - P_{\\text{prev}}))$$\nSubstituting this into the formula for $\\text{NPV}$, we obtain the general expression:\n$$\\text{NPV} = \\frac{\\text{Sp} \\times (1 - P_{\\text{prev}})}{((1 - \\text{Se}) \\times P_{\\text{prev}}) + \\text{Sp}(1 - P_{\\text{prev}})}$$\n\nNow, we compute the numerical values for $\\text{PPV}$ and $\\text{NPV}$ using the given data: $\\text{Se} = 0.60$, $\\text{Sp} = 0.90$, and $P_{\\text{prev}} = 0.20$.\n\nFor the $\\text{PPV}$:\n$$\\text{PPV} = \\frac{0.60 \\times 0.20}{(0.60 \\times 0.20) + (1 - 0.90)(1 - 0.20)}$$\n$$\\text{PPV} = \\frac{0.12}{0.12 + (0.10)(0.80)}$$\n$$\\text{PPV} = \\frac{0.12}{0.12 + 0.08}$$\n$$\\text{PPV} = \\frac{0.12}{0.20} = 0.60$$\n\nFor the $\\text{NPV}$:\n$$\\text{NPV} = \\frac{0.90 \\times (1 - 0.20)}{((1 - 0.60) \\times 0.20) + 0.90(1 - 0.20)}$$\n$$\\text{NPV} = \\frac{0.90 \\times 0.80}{(0.40 \\times 0.20) + (0.90 \\times 0.80)}$$\n$$\\text{NPV} = \\frac{0.72}{0.08 + 0.72}$$\n$$\\text{NPV} = \\frac{0.72}{0.80} = 0.90$$\n\nThe problem requires the final answer to be rounded to three significant figures. The calculated values are $\\text{PPV} = 0.60$ and $\\text{NPV} = 0.90$. To express these with three significant figures, we write them as $0.600$ and $0.900$, respectively. The final answer is to be reported as a row vector.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.600 & 0.900\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "When a liver mass is detected, a biopsy is often the definitive next step, but distinguishing early malignancy from regenerative changes in a cirrhotic liver can be challenging. This practice exercise challenges you to think like a pathologist by formalizing a diagnostic algorithm for hepatocellular carcinoma based on key microscopic features . You will learn to weigh evidence from architectural disorganization and cellular atypia, a fundamental skill for making an accurate diagnosis from tissue samples.",
            "id": "4380843",
            "problem": "You are tasked with formalizing a rule-based diagnostic algorithm for hepatocellular carcinoma (HCC) on core biopsy in a cirrhotic liver using three histologic features measurable on routine stains: increased nuclear-to-cytoplasmic ratio (N:C), nucleolar prominence, and thickened hepatocyte plates (trabeculae). Base your construction on the following foundational definitions and well-tested observations in hepatopathology: (i) malignancy is inferred from a combination of cytologic atypia and architectural disorganization; (ii) reactive hepatocytes in cirrhosis may show cytologic atypia without frank architectural disruption; (iii) hepatocyte plates thicker than normal reflect architectural derangement, with plates greater than $3$ cells across being strongly associated with neoplasia; (iv) normal or regenerative hepatocytes typically have a median $N:C$ near $0.3$ to $0.4$, whereas malignant hepatocytes often have a median $N:C$ exceeding $0.5$ to $0.6$; (v) prominent nucleoli occur in a minority of benign regenerative settings but are substantially more frequent in malignancy. You must set explicit decision thresholds on each feature and specify logical combinations that trigger an HCC diagnosis.\n\nYou have the following empirical baselines from the literature-quality observations to guide threshold selection: in cirrhotic regenerative nodules, plates greater than $3$ cells across are virtually absent across low-power fields (typically less than $1\\%$ of fields), median $N:C$ rarely exceeds $0.45$, and cells with prominent nucleoli comprise less than $5\\%$ of hepatocytes; in established hepatocellular carcinoma, plates greater than $3$ cells across occupy at least $15\\%$ to $20\\%$ of low-power fields in most cases, median $N:C$ is usually greater than $0.6$, and cells with prominent nucleoli comprise at least $20\\%$ of tumor cells in a substantial fraction of cases.\n\nA new cirrhotic core biopsy is evaluated as follows: $20$ nonoverlapping low-power fields are surveyed; in $6$ of $20$ fields ($30\\%$), hepatocyte plates exceed $3$ cells in thickness. A count of $200$ lesional hepatocytes yields a median $N:C$ of $0.55$, and $25\\%$ of cells show prominent, easily visible nucleoli.\n\nYou aim to select the single best algorithm below that: (a) encodes explicit thresholds for the three features; (b) achieves at least $95\\%$ specificity against regenerative nodules by prioritizing architectural abnormality over purely cytologic atypia; and (c) classifies the present biopsy as HCC. Which algorithm best satisfies these aims?\n\nA. Diagnose HCC if any $2$ of the following $3$ criteria are met: median $N:C \\ge 0.50$; nucleolar prominence in $\\ge 15\\%$ of cells; plates greater than $3$ cells across in $\\ge 20\\%$ of low-power fields. Otherwise, do not diagnose HCC.\n\nB. Diagnose HCC if plates greater than $3$ cells across are present in $\\ge 15\\%$ of low-power fields and at least $1$ of the following is present: median $N:C \\ge 0.55$ or nucleolar prominence in $\\ge 20\\%$ of cells. Otherwise, do not diagnose HCC.\n\nC. Diagnose HCC if any $1$ of the following is present: median $N:C \\ge 0.55$ or nucleolar prominence in $\\ge 20\\%$ of cells or plates greater than $3$ cells across in $\\ge 10\\%$ of low-power fields. Otherwise, do not diagnose HCC.\n\nD. Diagnose HCC only if all $3$ of the following stricter thresholds are met: median $N:C \\ge 0.60$; nucleolar prominence in $\\ge 25\\%$ of cells; plates greater than $3$ cells across in $\\ge 30\\%$ of low-power fields. Otherwise, do not diagnose HCC.",
            "solution": "The problem statement is evaluated as valid. It is scientifically grounded in the principles of histopathology, well-posed as a logical selection task, and objective in its language and data. All provided information is self-contained and sufficient to evaluate the proposed algorithms against the stated criteria.\n\nThe task is to select the best diagnostic algorithm from the given options based on three specific aims. The algorithm must formalize the diagnosis of hepatocellular carcinoma (HCC) using three features: thickened hepatocyte plates ($P_{\\text{thick}}$), increased nuclear-to-cytoplasmic ratio ($N:C$), and nucleolar prominence ($N_{\\text{prom}}$).\n\nThe aims for the algorithm are:\n(a) It must have explicit, quantitative thresholds.\n(b) It must achieve at least $95\\%$ specificity against regenerative nodules by prioritizing architectural abnormality over purely cytologic atypia. This is a crucial constraint, based on the provided principle that reactive hepatocytes in cirrhosis can show cytologic atypia (increased $N:C$ ratio, prominent nucleoli) without being malignant. Therefore, architectural disorganization (thickened plates) should be a primary or mandatory finding.\n(c) It must classify the provided case biopsy as HCC.\n\nThe data for the case biopsy are:\n- Thickened plates ($P_{\\text{thick}}$): Plates thicker than $3$ cells are found in $6$ of $20$ low-power fields, which is $30\\%$.\n- Nuclear-to-cytoplasmic ratio ($N:C$): The median $N:C$ is $0.55$.\n- Nucleolar prominence ($N_{\\text{prom}}$): Prominent nucleoli are seen in $25\\%$ of cells.\n\nThe empirical baselines for benign regenerative nodules, which the algorithm should not misclassify as HCC, are:\n- $P_{\\text{thick}} < 1\\%$ of fields.\n- Median $N:C$ rarely exceeds $0.45$.\n- $N_{\\text{prom}} < 5\\%$ of hepatocytes.\n\nWe will now evaluate each option against the three aims.\n\n**Option A:**\n- **Algorithm:** Diagnose HCC if any $2$ of the following $3$ criteria are met: median $N:C \\ge 0.50$; $N_{\\text{prom}} \\ge 15\\%$; $P_{\\text{thick}} \\ge 20\\%$.\n- **Evaluation:**\n    1. **Aim (a) - Explicit Thresholds:** This aim is met. The thresholds are $0.50$, $15\\%$, and $20\\%$.\n    2. **Aim (c) - Classify Case as HCC:**\n        - Is median $N:C \\ge 0.50$? Yes, $0.55 \\ge 0.50$.\n        - Is $N_{\\text{prom}} \\ge 15\\%$? Yes, $25\\% \\ge 15\\%$.\n        - Is $P_{\\text{thick}} \\ge 20\\%$? Yes, $30\\% \\ge 20\\%$.\n        All three criteria are met. Since only $2$ are required, this algorithm diagnoses the case as HCC. This aim is met.\n    3. **Aim (b) - Specificity & Prioritizing Architecture:** This algorithm allows for an HCC diagnosis if the two cytologic criteria (median $N:C \\ge 0.50$ and $N_{\\text{prom}} \\ge 15\\%$) are met, even if the architectural criterion ($P_{\\text{thick}} \\ge 20\\%$) is not. This directly violates the requirement to prioritize architecture, as it would permit a diagnosis based on cytologic atypia alone, which can be seen in non-malignant reactive states. This leads to poor specificity. This aim is not met.\n- **Verdict:** Incorrect. The algorithm fails to satisfy Aim (b) by not prioritizing architectural abnormality, leading to a potential loss of specificity.\n\n**Option B:**\n- **Algorithm:** Diagnose HCC if $P_{\\text{thick}} \\ge 15\\%$ AND at least one of the following is present: median $N:C \\ge 0.55$ or $N_{\\text{prom}} \\ge 20\\%$.\n- **Evaluation:**\n    1. **Aim (a) - Explicit Thresholds:** This aim is met. The thresholds are $15\\%$, $0.55$, and $20\\%$.\n    2. **Aim (c) - Classify Case as HCC:**\n        - First, check the mandatory architectural criterion: Is $P_{\\text{thick}} \\ge 15\\%$? Yes, $30\\% \\ge 15\\%$.\n        - Second, check the cytologic criteria (at least one must be met): Is median $N:C \\ge 0.55$? Yes, $0.55 \\ge 0.55$. Is $N_{\\text{prom}} \\ge 20\\%$? Yes, $25\\% \\ge 20\\%$.\n        Since the mandatory architectural criterion and both cytologic criteria are met, this algorithm diagnoses the case as HCC. This aim is met.\n    3. **Aim (b) - Specificity & Prioritizing Architecture:** The logical structure of this rule is `(Architectural criterion) AND (at least one Cytologic criterion)`. This explicitly makes architectural abnormality a prerequisite for diagnosis, thus satisfying the instruction to prioritize it. A case with only cytologic atypia would not be diagnosed as HCC. Furthermore, the thresholds ($15\\%$ for $P_{\\text{thick}}$, $0.55$ for $N:C$, $20\\%$ for $N_{\\text{prom}}$) are set well above the upper limits for regenerative nodules ($<1\\%$, $<0.45$, $<5\\%$, respectively), ensuring high specificity. This aim is met.\n- **Verdict:** Correct. This algorithm satisfies all three aims. It correctly classifies the case, ensures high specificity by making architectural abnormality a mandatory requirement, and uses explicit thresholds.\n\n**Option C:**\n- **Algorithm:** Diagnose HCC if any $1$ of the following is present: median $N:C \\ge 0.55$ or $N_{\\text{prom}} \\ge 20\\%$ or $P_{\\text{thick}} \\ge 10\\%$.\n- **Evaluation:**\n    1. **Aim (a) - Explicit Thresholds:** This aim is met. The thresholds are $0.55$, $20\\%$, and $10\\%$.\n    2. **Aim (c) - Classify Case as HCC:**\n        - Is median $N:C \\ge 0.55$? Yes, $0.55 \\ge 0.55$.\n        Since only one criterion is needed, this algorithm diagnoses the case as HCC. This aim is met.\n    3. **Aim (b) - Specificity & Prioritizing Architecture:** The \"any $1$\" (logical OR) structure is a major flaw. It allows for an HCC diagnosis based on any single feature, including cytologic features alone. This directly contravenes the principle of prioritizing architecture to distinguish from reactive atypia. For example, a reactive nodule with a median $N:C$ of $0.56$ but no other abnormalities would be incorrectly diagnosed as HCC. This aim is not met.\n- **Verdict:** Incorrect. The algorithm fails to satisfy Aim (b) due to its \"OR\" logic, which results in low specificity.\n\n**Option D:**\n- **Algorithm:** Diagnose HCC only if all $3$ of the following stricter thresholds are met: median $N:C \\ge 0.60$; $N_{\\text{prom}} \\ge 25\\%$; $P_{\\text{thick}} \\ge 30\\%$.\n- **Evaluation:**\n    1. **Aim (a) - Explicit Thresholds:** This aim is met. The thresholds are $0.60$, $25\\%$, and $30\\%$.\n    2. **Aim (c) - Classify Case as HCC:**\n        - Is median $N:C \\ge 0.60$? No, $0.55 < 0.60$.\n        - Is $N_{\\text{prom}} \\ge 25\\%$? Yes, $25\\% \\ge 25\\%$.\n        - Is $P_{\\text{thick}} \\ge 30\\%$? Yes, $30\\% \\ge 30\\%$.\n        Since the algorithm requires all three criteria to be met, and the $N:C$ criterion is not met, this algorithm does not diagnose the case as HCC. This aim is not met.\n    3. **Aim (b) - Specificity & Prioritizing Architecture:** This algorithm requires all three features, including the architectural one, and sets very high thresholds. It would have excellent specificity. This aim is met. However, failing Aim (c) is a disqualifier.\n- **Verdict:** Incorrect. The algorithm is too strict and fails to classify the given case as HCC, thus failing to meet Aim (c).\n\n**Conclusion:**\nOnly Option B successfully meets all three required aims: it uses explicit thresholds, prioritizes architectural derangement to ensure high specificity against benign mimics, and correctly classifies the specified biopsy as HCC.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Pathologists often face tumors with overlapping features, making diagnosis a complex puzzle. This final exercise tackles a classic diagnostic challenge: distinguishing a stroma-rich (scirrhous) hepatocellular carcinoma from an intrahepatic cholangiocarcinoma, its primary mimic . Through this problem, you will practice using immunohistochemical staining patterns as a crucial ancillary tool to determine a tumor's lineage and resolve diagnostic ambiguity.",
            "id": "4380815",
            "problem": "A liver resection shows a malignant epithelial tumor composed of nests and trabeculae of polygonal cells permeated by abundant fibrous stroma. You are asked to construct diagnostic criteria that reliably distinguish scirrhous hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (iCCA) using only two classes of observations: the proportion of tumor area occupied by fibrous stroma, and the pattern of immunoreactivity with canalicular-type immunostains on immunohistochemistry (IHC), specifically polyclonal carcinoembryonic antigen (pCEA) and Cluster of Differentiation 10 (CD10). Base your reasoning on the following fundamental definitions and well-tested facts: hepatocytes form bile canaliculi between adjacent cells and can show a canalicular pattern of antigen localization with appropriate immunostains, whereas biliary epithelium forms true glands and elicits desmoplasia but lacks hepatocellular canaliculi; desmoplastic stroma can be biologically prominent in both scirrhous variants of HCC and in iCCA; the pattern of immunostaining (canalicular versus cytoplasmic or membranous non-canalicular) reflects underlying cellular architecture. Which of the following paired criteria best operationalize a distinction that is both sensitive to the scirrhous variant and specific for hepatocellular differentiation?\n\n- A. Define scirrhous HCC as a tumor with fibrous stroma occupying at least $50\\%$ of the tumor area and showing a canalicular pattern of pCEA or CD10 in tumor cells; define iCCA as a tumor of any stromal proportion that lacks canalicular staining, instead showing only cytoplasmic or non-canalicular membranous pCEA or CD10.\n\n- B. Define scirrhous HCC as a tumor with fibrous stroma occupying at least $10\\%$ of the tumor area and any positivity for pCEA or CD10 regardless of pattern; define iCCA as a tumor with fibrous stroma less than $10\\%$ or negative for these stains.\n\n- C. Define scirrhous HCC as a tumor with minimal stroma (at most $5\\%$), since typical HCCs are soft, and regard canalicular staining as non-essential; define iCCA as a tumor with abundant stroma (at least $50\\%$) and canalicular staining.\n\n- D. Define scirrhous HCC as a tumor with abundant stroma (at least $50\\%$) and absence of canalicular staining but diffuse cytokeratin $7$ (CK$7$) and cytokeratin $19$ (CK$19$) positivity; define iCCA as a tumor with abundant stroma and canalicular staining.\n\n- E. Define scirrhous HCC as a tumor that has either abundant stroma (at least $50\\%$) or canalicular staining with pCEA or CD10; define iCCA as a tumor that lacks both abundant stroma and canalicular staining.\n\nSelect the single best option.",
            "solution": "The problem is evaluated as valid, grounded in established histopathological and immunohistochemical principles for distinguishing liver tumors. The goal is to find the best criteria to separate scirrhous hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (iCCA) using stromal proportion and the IHC staining pattern of pCEA/CD10.\n\nThe key challenge is the overlap in a major feature: both scirrhous HCC and iCCA are characterized by abundant fibrous stroma (desmoplasia). Therefore, stromal proportion alone cannot be the sole differentiating factor. A useful criterion must combine sensitivity for the \"scirrhous\" variant with specificity for \"hepatocellular differentiation.\"\n\nLet's analyze the provided facts:\n1.  **Sensitivity for \"scirrhous\" variant:** The term \"scirrhous\" implies abundant stroma. Thus, a high stromal percentage (e.g., $\\ge 50\\%$) is a necessary feature to define this HCC subtype.\n2.  **Specificity for \"hepatocellular differentiation\":** The problem states that hepatocytes form bile canaliculi, while biliary epithelium (the origin of iCCA) does not. A canalicular staining pattern with pCEA or CD10 is a direct reflection of this underlying hepatocellular architecture. This feature is therefore highly specific for HCC.\n\nThe optimal diagnostic logic must combine these two elements. A diagnosis of scirrhous HCC requires evidence of both its scirrhous nature (abundant stroma) AND its hepatocellular origin (canalicular staining).\n\nNow we evaluate the options based on this logic:\n\n*   **A:** Defines scirrhous HCC by requiring **both** abundant stroma ($\\ge 50\\%$) **and** the specific canalicular staining pattern. This correctly combines sensitivity for the variant with specificity for the lineage. It correctly defines iCCA by the absence of this specific feature (lacking canalicular staining), which is the most reliable way to exclude HCC. This option is logically sound.\n*   **B:** Fails on specificity. It accepts \"any positivity regardless of pattern,\" which is incorrect as non-canalicular staining is not specific to HCC. The stromal threshold of $10\\%$ is also too low for a \"scirrhous\" diagnosis.\n*   **C:** Incorrectly reverses the core definitions. It assigns minimal stroma to scirrhous HCC and canalicular staining (a hepatocellular feature) to iCCA.\n*   **D:** Incorrectly reverses the staining logic, assigning canalicular staining to iCCA. It also introduces IHC markers (CK7, CK19) that are outside the scope defined by the problem statement.\n*   **E:** The use of \"either/or\" logic is a critical flaw. It would incorrectly classify a stroma-rich iCCA (which lacks canalicular staining) as a scirrhous HCC, failing the specificity requirement. It would also mislabel a conventional, stroma-poor HCC as \"scirrhous.\"\n\nTherefore, option A provides the only set of criteria that is both sensitive for the scirrhous variant of HCC and highly specific for hepatocellular differentiation, correctly resolving the diagnostic dilemma presented.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}